Author: Naranbhai, Vivek; Chang, Christina C; Beltran, Wilfredo F Garcia; Miller, Tyler E; Astudillo, Michael G; Villalba, Julian A; Yang, Diane; Gelfand, Jeffrey; Bernstein, Bradley E; Feldman, Jared; Hauser, Blake M; Caradonna, Timothy M; Alter, Galit; Murali, Mandakolathur R; Jasrasaria, Rashmi; Quinlan, Joan; Xerras, Dean C; Betancourt, Joseph R; Louis, David N; Schmidt, Aaron G; Lennerz, Jochen; Poznansky, Mark C; Iafrate, A John
Title: High seroprevalence of anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts Cord-id: 7qk4abxl Document date: 2020_9_9
ID: 7qk4abxl
Snippet: SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG- and 5.0% IgM-IgG+). 50.5% of participants reported no symptoms in the precedi
Document: SARS-CoV-2 antibody testing allows quantitative determination of disease prevalence, especially important in high-risk communities. We performed anonymized convenience sampling of 200 currently asymptomatic residents of Chelsea, the epicenter of COVID-19 illness in Massachusetts by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay. The seroprevalence was 31.5% (17.5% IgM+IgG+, 9.0% IgM+IgG- and 5.0% IgM-IgG+). 50.5% of participants reported no symptoms in the preceding 4 weeks, of which 24.8% (25/101) were seropositive, and 60% of these were IgM+IgG-. These data are the highest seroprevalence rates observed to date and highlight the significant burden of asymptomatic infection.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date